[go: up one dir, main page]

AU2003222034A1 - (-)-2-(1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl)-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof - Google Patents

(-)-2-(1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl)-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof

Info

Publication number
AU2003222034A1
AU2003222034A1 AU2003222034A AU2003222034A AU2003222034A1 AU 2003222034 A1 AU2003222034 A1 AU 2003222034A1 AU 2003222034 A AU2003222034 A AU 2003222034A AU 2003222034 A AU2003222034 A AU 2003222034A AU 2003222034 A1 AU2003222034 A1 AU 2003222034A1
Authority
AU
Australia
Prior art keywords
acetylaminoisoindoline
methylsulfonylethyl
dione
methoxyphenyl
ethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003222034A
Inventor
Chuansheng Ge
Hon-Wah Man
George W. Muller
Peter H. Schafer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of AU2003222034A1 publication Critical patent/AU2003222034A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003222034A 2002-03-20 2003-03-20 (-)-2-(1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl)-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof Abandoned AU2003222034A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US36651602P 2002-03-20 2002-03-20
US60/366,516 2002-03-20
US43844803P 2003-01-07 2003-01-07
US60/438,448 2003-01-07
PCT/US2003/008737 WO2003080048A1 (en) 2002-03-20 2003-03-20 (-)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof

Publications (1)

Publication Number Publication Date
AU2003222034A1 true AU2003222034A1 (en) 2003-10-08

Family

ID=28457138

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003222034A Abandoned AU2003222034A1 (en) 2002-03-20 2003-03-20 (-)-2-(1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl)-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof

Country Status (2)

Country Link
AU (1) AU2003222034A1 (en)
WO (1) WO2003080048A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004220607B2 (en) * 2003-03-06 2009-06-11 Celgene Corporation Selective cytokine inhibitory drugs for treating disorders of the central nervous system

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100539031B1 (en) 1996-08-12 2005-12-27 셀진 코포레이션 Novel immunotherapeutic agents and their use in the reduction of cytokine levels
US7776907B2 (en) 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
JP2006508131A (en) 2002-11-06 2006-03-09 セルジーン・コーポレーション Methods and compositions using selective cytokine inhibitors for the treatment and management of cancer and other diseases
JP2006507324A (en) * 2002-11-06 2006-03-02 セルジーン・コーポレーション Compositions comprising selective cytokine inhibitors for the treatment and management of myeloproliferative diseases and methods of use thereof
US9006267B2 (en) 2002-11-14 2015-04-14 Celgene Corporation Pharmaceutical compositions and dosage forms of thalidomide
US7230012B2 (en) * 2002-11-14 2007-06-12 Celgene Corporation Pharmaceutical compositions and dosage forms of thalidomide
US20040175382A1 (en) * 2003-03-06 2004-09-09 Schafer Peter H. Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
CA2563207A1 (en) * 2004-04-14 2005-11-24 Celgene Corporation Use of selective cytokine inhibitory drugs in myelodysplastic syndromes
CA2565445A1 (en) * 2004-05-05 2005-12-01 Celgene Corporation Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
WO2006093719A1 (en) * 2005-02-25 2006-09-08 Janssen Pharmaceutica, N.V. An efficient and stereoselective process for large scale synthesis of 3-(r)-3- (2,3-dihydrobenzofuran-5-yl)-1,2,3,4- tetrahydropyrrolo{3,4-b}quinolin-9-one
AU2010213936B2 (en) 2009-02-10 2014-07-31 Celgene Corporation Methods of using and compositions comprising PDE4 modulators for treatment, prevention and management of tuberculosis
WO2010130224A1 (en) 2009-05-14 2010-11-18 天津和美生物技术有限公司 Thiophene derivatives
MX341896B (en) 2010-06-15 2016-09-07 Celgene Corp * Biomarkers for the treatment of psoriasis.
CN106008313B (en) * 2010-12-22 2018-11-13 康塞特医药品有限公司 Substituted -1,3 derovatives of isoindoline
WO2012096884A1 (en) * 2011-01-10 2012-07-19 Celgene Corporation Phenethylsulfone isoindoline derivatives as inhibitors of pde 4 and/or cytokines
EP3010490A1 (en) * 2013-06-17 2016-04-27 Celgene Corporation Tablet formulations of (+)-2-[1 -(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
WO2015173792A1 (en) 2014-05-11 2015-11-19 Mapi Pharma Ltd. Amorphous form of apremilast
US20170087129A1 (en) 2014-05-16 2017-03-30 Celgene Corporation Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
CN106137986B (en) * 2015-03-09 2019-04-16 常州制药厂有限公司 A kind of Thalidomide piece and preparation method thereof
CN105085373B (en) * 2015-09-01 2018-02-09 苏州大学 Purification method of apremilast product
WO2017059040A1 (en) * 2015-09-29 2017-04-06 Pliva Hrvatska D.O.O. Processes for the preparation of apremilast and intermediates thereof
US10682336B2 (en) 2015-10-21 2020-06-16 Amgen Inc. PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004220607B2 (en) * 2003-03-06 2009-06-11 Celgene Corporation Selective cytokine inhibitory drugs for treating disorders of the central nervous system

Also Published As

Publication number Publication date
WO2003080048A1 (en) 2003-10-02

Similar Documents

Publication Publication Date Title
AU2003222034A1 (en) (-)-2-(1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl)-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
CY2019032I1 (en) (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULPHONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USE AND COMPOSITIONS THEREOF
EP1578396A3 (en) Methods and compositions concerning poxviruses and cancer
AU2003270015A1 (en) Compounds, compositions, and methods
AU2002363236A1 (en) Compounds, pharmaceutical compositions and methods of use therefor
AU2003267644A1 (en) Dental compositions and methods
AU2003248721A1 (en) Adsorbents, methods of preparation, and methods of use thereof
AU2003278478A1 (en) Sesquiterpene synthases and methods of use
AU2003241464A1 (en) Compositions and methods using proton pump inhibitors
AU2003300679A1 (en) User interface for alerts
AU2002320057A1 (en) Herbal composition for improving oral hygiene, and methods of using same
WO2004047628A8 (en) Methods of analyzing atrial fibrillations
AU2003286474A1 (en) Compositions, solutions, and methods used for transplantation
AU2003275268A1 (en) Hemostatic compositions and methods
AU2003299441A1 (en) Nf-hev compositions and methods of use
PL374646A1 (en) Novel nonsteroidal anti-inflammatory substances, compositions and methods for their use
AU2003296469A1 (en) Dental compositions including enzymes and methods
AU2003215796A1 (en) Audio distribution
AU2003214381A1 (en) Perfume gel composition
AU2002224938A1 (en) Compounds that affect CD83 expression, pharmaceutical compositions comprising said compounds and methods for identifying said compounds
ZA200600682B (en) (+)-2[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: Methods of using and compositions thereof
EP1576109A3 (en) Methods and compositions for categorizing patients
AU2003258937A1 (en) Naphthyl ether compounds and their use
AU2003217942A1 (en) Modulators of leukocyte activation, compositions, and methods of use
AU2003287703A1 (en) Audio over subsystem interface

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase